Biogen (BIIB) stock was hamstrung Wednesday on a mixed 2023 outlook that assumes expenses for new Alzheimer’s treatment will outpace its sales. X Despite beating fourth-quarter expectations, Bio...
Tag: Biogen
‘There is a lot that’s underestimated at Biogen’: CEO Viehbacher
Shares of Biogen Inc (NASDAQ: BIIB) have gained nearly 45% since late September but CEO Christopher Viehbacher says there’s still “a lot that’s underestimated” at Biogen. Highlights from CEO’s inter...
How To Take Advantage Of Today’s Generous Corporate Bond Yields
The desert of no yield Tim Graham/Getty Images The Federal Reserve imparted new meaning to quantitative easing and low interest rates both during and after the pandemic. Since then, we investors have ...
Here Are The Companies That Have Profited The Most During Inflation
Getty Images When it comes to inflation, there’s no shortage of blame to go around. First, the pandemic broke the global supply chain. Then stimulus payments set off a frenzy of consumer spending at...
Harley-Davidson, Visa, Microsoft, Biogen and more
A mechanic works on a motorcycle at a Harley-Davidson showroom and repair shop in Lindon, Utah, on Monday, April 19, 2021. George Frey | Bloomberg | Getty Images Check out the companies making headlin...
How Biogen Makes Money In 2022 And How They Defied Gravity
| Getty Images Key Takeaways Biogen has seen its stock price skyrocket after groundbreaking news about its new Alzheimer’s treatment that could improve the lives of millions of Americans, and bi...
Biogen Stock Flies On Upgrade; Why Alzheimer’s Is A $7 Billion Opportunity
Biogen (BIIB) could easily take on Roche (RHHBY) and Eli Lilly (LLY) in Alzheimer’s treatment, an analyst said Thursday as he updated Biogen stock. X In response, Biogen stock surged 6.4% to 269...
An Alzheimer’s Drug’s Big Surprise: What It Means
Until this past week, there seemed to be no answers to the Alzheimer’s puzzle. The leading theory of the disease, that it was caused by a buildup of beta amyloid plaque in the brain, had been disprove...
Healthcare And Biotech Outperform As Recession Fears Heat Up
Stocks fell sharply in September to this bear market’s new lows. Getty Images September lived up to its billing as a lackluster month for the stock market, as the S&P 500 lost another 9.1% t...
Biogen Stock Explodes Higher After Alzheimer’s Drug Succeeds In Final-Phase Test
Biogen stock exploded higher Wednesday — bringing shares of other Alzheimer’s plays with it — after its experimental treatment succeeded in a final-phase test. X The results are sorely needed fo...
Biogen stock pumps 48% amid upgrade. What to watch out for
Biogen Inc. (NASDAQ:BIIB) gained more than 48% on Wednesday’s stock premarket. The stock was among the top trends on popular social trading platforms. There were definite reasons. On Tuesday, company ...
Biogen stock shot up 40% on Wednesday: find out why
Shares of Biogen Inc (NASDAQ: BIIB) shot up 40% on Wednesday after the biotech firm said its experimental Alzheimer’s drug showed promising results in a Phase III trial. Why is it a big news for Bioge...
Biogen stock explodes higher after potential ‘mega blockbuster’ Alzheimer’s drug study
Biogen stock (BIIB) is booming amid as Wall Street speculates about a potential profit boom after a promising study detailed the company’s new Alzheimer’s drug in partnership with Japan’s ...
Apple, Netflix, Biogen, Canopy Growth and more
A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Check out the companies making headlines in midday trading. Apple — Apple shares fell 3.4% on Wednesday following a report that th...
Biogen, Thor Industries, Lyft and more
Check out the companies making headlines before the bell: Biogen (BIIB) – Biogen soared 45.6% in premarket trading after Biogen and Japanese partner Eisai said their experimental Alzheimer’s dru...
Biogen to pay $900 million to settle drug kickback allegations
A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen will pay $900 million to settle a lawsuit that alleged the company gave doctors kickbacks to encourage them prescribe its d...
Biogen tops Q2 2022 earnings and revenue estimates
Biogen Inc (NASDAQ: BIIB) has announced a Q2 2002 revenue of $2.589 billion. GAAP net income was $1.058 billion or $7.24 per diluted share, and non-GAAP net income was $767 million or earnings of $5....
Biogen Stock Falls Despite A ‘Fine’ Report And Guidance Raise — Here’s Why
Biogen‘s (BIIB) second-quarter report was “fine,” according to one analyst. But without an update on its strategy for life after Aduhelm, Biogen stock fell. X The company is at a tur...
Baker Hughes, Biogen, Netflix and more
Check out the companies making headlines before the bell: Baker Hughes (BKR) – The oilfield services company reported second-quarter adjusted earnings of 11 cents per share, just half of what analysts...
Biogen CEO Stepping Down After Struggles With Alzheimer’s Drug Aduhelm
Topline Biogen CEO Michel Vounatsos will step down as the company continues to cut about $1 billion in costs annually, Biogen said Tuesday, after Medicare limited coverage for its Alzheimer’s drug, Ad...
As Time Passes, and the Weather Warms, Putin’s Power Play in Europe Loses Force
Why isn’t Putin’s move to cut off natural-gas shipments to Poland and Bulgaria causing a bigger spike in prices? Elias Stein Text size Vladimir Putin’s move to cut off natural-gas shipments to Poland ...
Biogen Stock: Why One Analyst Says It’s ‘Too Good To Ignore’
Biogen stock looks “too good to ignore,” an analyst said Monday as he argued for the value of Biogen‘s (BIIB) base business despite its Alzheimer’s mishaps. X Wells Fargo analy...
Biogen needs ‘this’ to unlock a 60% upside in its stock
Biogen Inc (NASDAQ: BIIB) stock could shoot up 60% if the biotech company reports positive results for its investigational Alzheimer’s drug Lecanemab in fall of 2022, says Mohit Bansal. Bansal&r...
Biogen, Spirit, Robinhood and more
Check out the companies making headlines before the bell: Biogen (BIIB) – Biogen fell 1% in premarket trading after the government announced that Medicare will limit coverage for Aduhelm, Biogen’...
Biogen Stock: Will The $8 Billion Opportunity Materialize For Alzheimer’s Drugs?
Biogen stock popped Thursday after an analyst suggested the biotech company could reap $8 billion in sales of its Alzheimer’s treatments — assuming everything lines up properly. X But hours late...
Biogen vs Eli Lilly: Jim Cramer weighs in
Shares of Biogen Inc (NASDAQ: BIIB) are down about 8.0% on Wednesday after the U.S. Medicare programme refused to cover for its Alzheimer’s drug, Aduhelm, unless the patient is enrolled in an approved...
Biogen Stock Has Fallen 50%. Why It’s Time to Buy.
Text size Biogen’s Alzheimer’s disease treatment was once expected to be a megablockbuster. Dominick Reuter/AFP via Getty Images Shares of the biotech firm Biogen are down 50% since June 1...